Curative therapies - allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and non-myeloablative conditioning in sickle cell disease

Sickle cell disease (SCD) chronically damages multiple organs over the life time of affected individuals. Allogeneic hematopoietic cell transplantation (allo-HCT) is the most studied curative intervention. Fully matched related marrow, peripheral blood derived, or cord blood HCT have the best transplant outcome for symptomatic patients with SCD. For patients with asymptomatic or milder disease who have this donor option available, risks and benefits of HCT should be discussed among the patient, family, treating hematologist, and transplant physician, and decision to proceed to HCT should be individualized.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research